#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Obesity and related disorders are widely perceived by both the public and the scientific community as a major and growing threat to global human health ; more than 2 billion people worldwide are currently overweight or obese , and obesity is associated with an increased hazard for a range of ailments , including type-2 diabetes , cardiovascular diseases and hypertension , multiple cancer types , chronic inflammatory diseases , dementia , and neurodegenerative diseases .
3-1	17-24	Obesity	abstract|abstract[4]	new|new[4]	coref|coref|coref|coref	3-40|14-12[105_4]|3-40|14-12[105_4]
3-2	25-28	and	abstract[4]	new[4]	_	_
3-3	29-36	related	abstract[4]|abstract[5]	new[4]|new[5]	coref	14-14[106_5]
3-4	37-46	disorders	abstract[4]|abstract[5]	new[4]|new[5]	_	_
3-5	47-50	are	_	_	_	_
3-6	51-57	widely	_	_	_	_
3-7	58-67	perceived	_	_	_	_
3-8	68-70	by	_	_	_	_
3-9	71-75	both	person[6]	new[6]	_	_
3-10	76-79	the	person[6]	new[6]	_	_
3-11	80-86	public	person[6]	new[6]	_	_
3-12	87-90	and	_	_	_	_
3-13	91-94	the	organization[7]	new[7]	_	_
3-14	95-105	scientific	organization[7]	new[7]	_	_
3-15	106-115	community	organization[7]	new[7]	_	_
3-16	116-118	as	organization[7]	new[7]	_	_
3-17	119-120	a	organization[7]	new[7]	_	_
3-18	121-126	major	organization[7]	new[7]	_	_
3-19	127-130	and	organization[7]	new[7]	_	_
3-20	131-138	growing	organization[7]	new[7]	_	_
3-21	139-145	threat	organization[7]	new[7]	_	_
3-22	146-148	to	organization[7]	new[7]	_	_
3-23	149-155	global	organization[7]|abstract[8]	new[7]|new[8]	_	_
3-24	156-161	human	organization[7]|abstract[8]	new[7]|new[8]	_	_
3-25	162-168	health	organization[7]|abstract[8]	new[7]|new[8]	_	_
3-26	169-170	;	_	_	_	_
3-27	171-175	more	person[11]	new[11]	_	_
3-28	176-180	than	person[11]	new[11]	_	_
3-29	181-182	2	quantity|person[11]	new|new[11]	_	_
3-30	183-190	billion	abstract|person[11]	new|new[11]	_	_
3-31	191-197	people	person[11]	new[11]	_	_
3-32	198-207	worldwide	person[11]	new[11]	_	_
3-33	208-211	are	_	_	_	_
3-34	212-221	currently	_	_	_	_
3-35	222-232	overweight	_	_	_	_
3-36	233-235	or	_	_	_	_
3-37	236-241	obese	_	_	_	_
3-38	242-243	,	_	_	_	_
3-39	244-247	and	_	_	_	_
3-40	248-255	obesity	abstract	giv	coref	5-20
3-41	256-258	is	_	_	_	_
3-42	259-269	associated	_	_	_	_
3-43	270-274	with	_	_	_	_
3-44	275-277	an	abstract[13]	new[13]	_	_
3-45	278-287	increased	abstract[13]	new[13]	_	_
3-46	288-294	hazard	abstract[13]	new[13]	_	_
3-47	295-298	for	abstract[13]	new[13]	_	_
3-48	299-300	a	abstract[13]	new[13]	_	_
3-49	301-306	range	abstract[13]	new[13]	_	_
3-50	307-309	of	abstract[13]	new[13]	_	_
3-51	310-318	ailments	abstract[13]|abstract[14]	new[13]|new[14]	_	_
3-52	319-320	,	abstract[13]|abstract[14]	new[13]|new[14]	_	_
3-53	321-330	including	abstract[13]|abstract[14]	new[13]|new[14]	_	_
3-54	331-337	type-2	abstract[13]|abstract[14]|abstract[15]	new[13]|new[14]|new[15]	_	_
3-55	338-346	diabetes	abstract[13]|abstract[14]|abstract[15]	new[13]|new[14]|new[15]	_	_
3-56	347-348	,	abstract[13]|abstract[14]	new[13]|new[14]	_	_
3-57	349-363	cardiovascular	abstract[13]|abstract[14]|abstract[16]	new[13]|new[14]|new[16]	_	_
3-58	364-372	diseases	abstract[13]|abstract[14]|abstract[16]	new[13]|new[14]|new[16]	_	_
3-59	373-376	and	abstract[13]|abstract[14]	new[13]|new[14]	_	_
3-60	377-389	hypertension	abstract[13]|abstract[14]|abstract	new[13]|new[14]|new	_	_
3-61	390-391	,	abstract[13]|abstract[14]	new[13]|new[14]	_	_
3-62	392-400	multiple	abstract[13]|abstract[14]|abstract[19]	new[13]|new[14]|new[19]	_	_
3-63	401-407	cancer	abstract[13]|abstract[14]|abstract|abstract[19]	new[13]|new[14]|new|new[19]	_	_
3-64	408-413	types	abstract[13]|abstract[14]|abstract[19]	new[13]|new[14]|new[19]	_	_
3-65	414-415	,	abstract[13]|abstract[14]	new[13]|new[14]	_	_
3-66	416-423	chronic	abstract[13]|abstract[14]|abstract[20]	new[13]|new[14]|new[20]	_	_
3-67	424-436	inflammatory	abstract[13]|abstract[14]|abstract[20]	new[13]|new[14]|new[20]	_	_
3-68	437-445	diseases	abstract[13]|abstract[14]|abstract[20]	new[13]|new[14]|new[20]	_	_
3-69	446-447	,	abstract[13]|abstract[14]	new[13]|new[14]	_	_
3-70	448-456	dementia	abstract[13]|abstract[14]|abstract	new[13]|new[14]|new	_	_
3-71	457-458	,	abstract[13]|abstract[14]	new[13]|new[14]	_	_
3-72	459-462	and	abstract[13]|abstract[14]	new[13]|new[14]	_	_
3-73	463-480	neurodegenerative	abstract[13]|abstract[14]|abstract[22]	new[13]|new[14]|new[22]	_	_
3-74	481-489	diseases	abstract[13]|abstract[14]|abstract[22]	new[13]|new[14]|new[22]	_	_
3-75	490-491	.	_	_	_	_

#Text=All these complications lead to a shortened life expectancy and have a high economic impact on healthcare systems .
4-1	492-495	All	abstract[23]	new[23]	_	_
4-2	496-501	these	abstract[23]	new[23]	_	_
4-3	502-515	complications	abstract[23]	new[23]	_	_
4-4	516-520	lead	_	_	_	_
4-5	521-523	to	_	_	_	_
4-6	524-525	a	abstract[25]	new[25]	_	_
4-7	526-535	shortened	abstract[25]	new[25]	_	_
4-8	536-540	life	abstract|abstract[25]	new|new[25]	_	_
4-9	541-551	expectancy	abstract[25]	new[25]	_	_
4-10	552-555	and	_	_	_	_
4-11	556-560	have	_	_	_	_
4-12	561-562	a	abstract[26]	new[26]	_	_
4-13	563-567	high	abstract[26]	new[26]	_	_
4-14	568-576	economic	abstract[26]	new[26]	_	_
4-15	577-583	impact	abstract[26]	new[26]	_	_
4-16	584-586	on	abstract[26]	new[26]	_	_
4-17	587-597	healthcare	abstract[26]|organization|abstract[28]	new[26]|new|new[28]	_	_
4-18	598-605	systems	abstract[26]|abstract[28]	new[26]|new[28]	_	_
4-19	606-607	.	_	_	_	_

#Text=Lifestyle changes ( such as diet modification , physical activity , and behavioral interventions ) are the cornerstones of obesity treatment but maintaining a healthy lifestyle is often perceived as challenging .
5-1	608-617	Lifestyle	abstract|abstract[30]	new|new[30]	coref|coref|coref|coref	5-17[35_30]|5-24[38_0]|5-17[35_30]|5-24[38_0]
5-2	618-625	changes	abstract[30]	new[30]	_	_
5-3	626-627	(	abstract[30]	new[30]	_	_
5-4	628-632	such	abstract[30]	new[30]	_	_
5-5	633-635	as	abstract[30]	new[30]	_	_
5-6	636-640	diet	abstract[30]|event|abstract[32]	new[30]|new|new[32]	_	_
5-7	641-653	modification	abstract[30]|abstract[32]	new[30]|new[32]	_	_
5-8	654-655	,	abstract[30]	new[30]	_	_
5-9	656-664	physical	abstract[30]|abstract[33]	new[30]|new[33]	coref	21-26[183_33]
5-10	665-673	activity	abstract[30]|abstract[33]	new[30]|new[33]	_	_
5-11	674-675	,	abstract[30]	new[30]	_	_
5-12	676-679	and	abstract[30]	new[30]	_	_
5-13	680-690	behavioral	abstract[30]|event[34]	new[30]|new[34]	coref	6-8[42_34]
5-14	691-704	interventions	abstract[30]|event[34]	new[30]|new[34]	_	_
5-15	705-706	)	abstract[30]	new[30]	_	_
5-16	707-710	are	_	_	_	_
5-17	711-714	the	abstract[35]	giv[35]	coref	15-47[0_35]
5-18	715-727	cornerstones	abstract[35]	giv[35]	_	_
5-19	728-730	of	abstract[35]	giv[35]	_	_
5-20	731-738	obesity	abstract[35]|abstract|event[37]	giv[35]|giv|new[37]	coref|coref|coref|coref	7-4|25-20[212_37]|7-4|25-20[212_37]
5-21	739-748	treatment	abstract[35]|event[37]	giv[35]|new[37]	_	_
5-22	749-752	but	_	_	_	_
5-23	753-764	maintaining	_	_	_	_
5-24	765-766	a	abstract[38]	giv[38]	_	_
5-25	767-774	healthy	abstract[38]	giv[38]	_	_
5-26	775-784	lifestyle	abstract[38]	giv[38]	_	_
5-27	785-787	is	_	_	_	_
5-28	788-793	often	_	_	_	_
5-29	794-803	perceived	_	_	_	_
5-30	804-806	as	_	_	_	_
5-31	807-818	challenging	_	_	_	_
5-32	819-820	.	_	_	_	_

#Text=Alternatively , pharmacotherapy and bariatric surgery represent more “ aggressive ” interventions , and are applicable only if the problem is severe .
6-1	821-834	Alternatively	_	_	_	_
6-2	835-836	,	_	_	_	_
6-3	837-852	pharmacotherapy	abstract	new	coref	7-1[44_0]
6-4	853-856	and	_	_	_	_
6-5	857-866	bariatric	abstract|event[41]	new|new[41]	_	_
6-6	867-874	surgery	event[41]	new[41]	_	_
6-7	875-884	represent	_	_	_	_
6-8	885-889	more	event[42]	giv[42]	_	_
6-9	890-891	“	event[42]	giv[42]	_	_
6-10	892-902	aggressive	event[42]	giv[42]	_	_
6-11	903-904	”	event[42]	giv[42]	_	_
6-12	905-918	interventions	event[42]	giv[42]	_	_
6-13	919-920	,	_	_	_	_
6-14	921-924	and	_	_	_	_
6-15	925-928	are	_	_	_	_
6-16	929-939	applicable	_	_	_	_
6-17	940-944	only	_	_	_	_
6-18	945-947	if	_	_	_	_
6-19	948-951	the	abstract[43]	new[43]	_	_
6-20	952-959	problem	abstract[43]	new[43]	_	_
6-21	960-962	is	_	_	_	_
6-22	963-969	severe	_	_	_	_
6-23	970-971	.	_	_	_	_

#Text=Current pharmacotherapy for obesity relies on a few drugs that are approved only for patients with BMI > 30.
7-1	972-979	Current	abstract[44]	giv[44]	_	_
7-2	980-995	pharmacotherapy	abstract[44]	giv[44]	_	_
7-3	996-999	for	abstract[44]	giv[44]	_	_
7-4	1000-1007	obesity	abstract[44]|abstract	giv[44]|giv	coref	14-12
7-5	1008-1014	relies	_	_	_	_
7-6	1015-1017	on	_	_	_	_
7-7	1018-1019	a	substance[46]	new[46]	coref	8-17[55_46]
7-8	1020-1023	few	substance[46]	new[46]	_	_
7-9	1024-1029	drugs	substance[46]	new[46]	_	_
7-10	1030-1034	that	_	_	_	_
7-11	1035-1038	are	_	_	_	_
7-12	1039-1047	approved	_	_	_	_
7-13	1048-1052	only	_	_	_	_
7-14	1053-1056	for	_	_	_	_
7-15	1057-1065	patients	person[47]	new[47]	_	_
7-16	1066-1070	with	person[47]	new[47]	_	_
7-17	1071-1074	BMI	person[47]|organization[48]	new[47]|new[48]	_	_
7-18	1075-1076	>	person[47]|organization[48]	new[47]|new[48]	_	_
7-19	1077-1080	30.	person[47]|organization[48]|quantity	new[47]|new[48]|new	_	_

#Text=With the only exception of orlistat ( which decreases fat absorption by inhibiting lipases ) , most of these drugs act through the central nervous system to reduce food intake ( via reduction of appetite or enhancement of satiety ) .
8-1	1081-1085	With	_	_	_	_
8-2	1086-1089	the	abstract[50]	new[50]	_	_
8-3	1090-1094	only	abstract[50]	new[50]	_	_
8-4	1095-1104	exception	abstract[50]	new[50]	_	_
8-5	1105-1107	of	abstract[50]	new[50]	_	_
8-6	1108-1116	orlistat	abstract[50]|substance	new[50]|new	_	_
8-7	1117-1118	(	_	_	_	_
8-8	1119-1124	which	_	_	_	_
8-9	1125-1134	decreases	_	_	_	_
8-10	1135-1138	fat	substance|abstract[53]	new|new[53]	coref|coref	15-9|15-9
8-11	1139-1149	absorption	abstract[53]	new[53]	_	_
8-12	1150-1152	by	_	_	_	_
8-13	1153-1163	inhibiting	_	_	_	_
8-14	1164-1171	lipases	substance	new	_	_
8-15	1172-1173	)	_	_	_	_
8-16	1174-1175	,	_	_	_	_
8-17	1176-1180	most	substance[55]	giv[55]	_	_
8-18	1181-1183	of	substance[55]	giv[55]	_	_
8-19	1184-1189	these	substance[55]	giv[55]	_	_
8-20	1190-1195	drugs	substance[55]	giv[55]	_	_
8-21	1196-1199	act	_	_	_	_
8-22	1200-1207	through	_	_	_	_
8-23	1208-1211	the	object[56]	new[56]	_	_
8-24	1212-1219	central	object[56]	new[56]	_	_
8-25	1220-1227	nervous	object[56]	new[56]	_	_
8-26	1228-1234	system	object[56]	new[56]	_	_
8-27	1235-1237	to	_	_	_	_
8-28	1238-1244	reduce	_	_	_	_
8-29	1245-1249	food	substance|event[58]	new|new[58]	_	_
8-30	1250-1256	intake	event[58]	new[58]	_	_
8-31	1257-1258	(	event[58]	new[58]	_	_
8-32	1259-1262	via	event[58]	new[58]	_	_
8-33	1263-1272	reduction	event[58]|abstract[59]	new[58]|new[59]	_	_
8-34	1273-1275	of	event[58]|abstract[59]	new[58]|new[59]	_	_
8-35	1276-1284	appetite	event[58]|abstract[59]|abstract	new[58]|new[59]|new	_	_
8-36	1285-1287	or	event[58]|abstract[59]	new[58]|new[59]	_	_
8-37	1288-1299	enhancement	event[58]|abstract[59]|abstract[61]	new[58]|new[59]|new[61]	_	_
8-38	1300-1302	of	event[58]|abstract[59]|abstract[61]	new[58]|new[59]|new[61]	_	_
8-39	1303-1310	satiety	event[58]|abstract[59]|abstract[61]|abstract	new[58]|new[59]|new[61]|new	_	_
8-40	1311-1312	)	event[58]	new[58]	_	_
8-41	1313-1314	.	_	_	_	_

#Text=However , the use of these treatments may lead to severe adverse effects and a long-term prescription is usually not recommended .
9-1	1315-1322	However	_	_	_	_
9-2	1323-1324	,	_	_	_	_
9-3	1325-1328	the	event[63]	new[63]	_	_
9-4	1329-1332	use	event[63]	new[63]	_	_
9-5	1333-1335	of	event[63]	new[63]	_	_
9-6	1336-1341	these	event[63]|abstract[64]	new[63]|new[64]	coref	10-25[74_64]
9-7	1342-1352	treatments	event[63]|abstract[64]	new[63]|new[64]	_	_
9-8	1353-1356	may	_	_	_	_
9-9	1357-1361	lead	_	_	_	_
9-10	1362-1364	to	_	_	_	_
9-11	1365-1371	severe	abstract[65]	new[65]	coref	10-30[76_65]
9-12	1372-1379	adverse	abstract[65]	new[65]	_	_
9-13	1380-1387	effects	abstract[65]	new[65]	_	_
9-14	1388-1391	and	_	_	_	_
9-15	1392-1393	a	event[66]	new[66]	_	_
9-16	1394-1403	long-term	event[66]	new[66]	_	_
9-17	1404-1416	prescription	event[66]	new[66]	_	_
9-18	1417-1419	is	_	_	_	_
9-19	1420-1427	usually	_	_	_	_
9-20	1428-1431	not	_	_	_	_
9-21	1432-1443	recommended	_	_	_	_
9-22	1444-1445	.	_	_	_	_

#Text=A nutraceutical approach could be a useful supporting tool to treat overweight people , since the use of natural compounds offers clear advantages over drug treatments in terms of adverse side effects , suitability for chronic treatments , marketability , and safety .
10-1	1446-1447	A	abstract[67]	new[67]	coref	10-6[68_67]
10-2	1448-1461	nutraceutical	abstract[67]	new[67]	_	_
10-3	1462-1470	approach	abstract[67]	new[67]	_	_
10-4	1471-1476	could	_	_	_	_
10-5	1477-1479	be	_	_	_	_
10-6	1480-1481	a	abstract[68]	giv[68]	_	_
10-7	1482-1488	useful	abstract[68]	giv[68]	_	_
10-8	1489-1499	supporting	abstract[68]	giv[68]	_	_
10-9	1500-1504	tool	abstract[68]	giv[68]	_	_
10-10	1505-1507	to	_	_	_	_
10-11	1508-1513	treat	_	_	_	_
10-12	1514-1524	overweight	person[69]	giv[69]	_	_
10-13	1525-1531	people	person[69]	giv[69]	_	_
10-14	1532-1533	,	_	_	_	_
10-15	1534-1539	since	_	_	_	_
10-16	1540-1543	the	event[70]	new[70]	_	_
10-17	1544-1547	use	event[70]	new[70]	_	_
10-18	1548-1550	of	event[70]	new[70]	_	_
10-19	1551-1558	natural	event[70]|substance[71]	new[70]|new[71]	_	_
10-20	1559-1568	compounds	event[70]|substance[71]	new[70]|new[71]	_	_
10-21	1569-1575	offers	_	_	_	_
10-22	1576-1581	clear	abstract[72]	new[72]	_	_
10-23	1582-1592	advantages	abstract[72]	new[72]	_	_
10-24	1593-1597	over	abstract[72]	new[72]	_	_
10-25	1598-1602	drug	abstract[72]|substance|abstract[74]	new[72]|new|giv[74]	_	_
10-26	1603-1613	treatments	abstract[72]|abstract[74]	new[72]|giv[74]	_	_
10-27	1614-1616	in	abstract[72]|abstract[74]	new[72]|giv[74]	_	_
10-28	1617-1622	terms	abstract[72]|abstract[74]	new[72]|giv[74]	_	_
10-29	1623-1625	of	abstract[72]|abstract[74]	new[72]|giv[74]	_	_
10-30	1626-1633	adverse	abstract[72]|abstract[74]|abstract[76]	new[72]|giv[74]|giv[76]	coref	14-8[103_76]
10-31	1634-1638	side	abstract[72]|abstract[74]|abstract|abstract[76]	new[72]|giv[74]|new|giv[76]	_	_
10-32	1639-1646	effects	abstract[72]|abstract[74]|abstract[76]	new[72]|giv[74]|giv[76]	_	_
10-33	1647-1648	,	abstract[72]|abstract[74]|abstract[76]	new[72]|giv[74]|giv[76]	_	_
10-34	1649-1660	suitability	abstract[72]|abstract[74]|abstract[76]|abstract[77]	new[72]|giv[74]|giv[76]|new[77]	_	_
10-35	1661-1664	for	abstract[72]|abstract[74]|abstract[76]|abstract[77]	new[72]|giv[74]|giv[76]|new[77]	_	_
10-36	1665-1672	chronic	abstract[72]|abstract[74]|abstract[76]|abstract[77]	new[72]|giv[74]|giv[76]|new[77]	_	_
10-37	1673-1683	treatments	abstract[72]|abstract[74]|abstract[76]|abstract[77]	new[72]|giv[74]|giv[76]|new[77]	_	_
10-38	1684-1685	,	abstract[72]|abstract[74]|abstract[76]|abstract[77]	new[72]|giv[74]|giv[76]|new[77]	_	_
10-39	1686-1699	marketability	abstract[72]|abstract[74]|abstract[76]|abstract[77]|abstract	new[72]|giv[74]|giv[76]|new[77]|new	_	_
10-40	1700-1701	,	abstract[72]|abstract[74]|abstract[76]|abstract[77]	new[72]|giv[74]|giv[76]|new[77]	_	_
10-41	1702-1705	and	abstract[72]|abstract[74]|abstract[76]|abstract[77]	new[72]|giv[74]|giv[76]|new[77]	_	_
10-42	1706-1712	safety	abstract[72]|abstract[74]|abstract[76]|abstract[77]|abstract	new[72]|giv[74]|giv[76]|new[77]|new	coref	13-8[101_0]
10-43	1713-1714	.	_	_	_	_

#Text=Here we focus our attention on pterostilbene ( Pt ; 3,5-dimethylresveratrol ) , an analogue of resveratrol that differs from the latter for the presence of two methyl groups .
11-1	1715-1719	Here	_	_	_	_
11-2	1720-1722	we	person	acc	ana	11-4
11-3	1723-1728	focus	_	_	_	_
11-4	1729-1732	our	person|abstract[82]	giv|new[82]	ana|ana	25-16|25-16
11-5	1733-1742	attention	abstract[82]	new[82]	_	_
11-6	1743-1745	on	_	_	_	_
11-7	1746-1759	pterostilbene	abstract	new	appos	11-9
11-8	1760-1761	(	_	_	_	_
11-9	1762-1764	Pt	abstract	giv	coref	14-1
11-10	1765-1766	;	_	_	_	_
11-11	1767-1790	3,5-dimethylresveratrol	abstract	new	_	_
11-12	1791-1792	)	_	_	_	_
11-13	1793-1794	,	_	_	_	_
11-14	1795-1797	an	substance[86]	new[86]	ana	12-1[0_86]
11-15	1798-1806	analogue	substance[86]	new[86]	_	_
11-16	1807-1809	of	substance[86]	new[86]	_	_
11-17	1810-1821	resveratrol	substance[86]|object	new[86]|new	coref	12-16[99_0]
11-18	1822-1826	that	_	_	_	_
11-19	1827-1834	differs	_	_	_	_
11-20	1835-1839	from	_	_	_	_
11-21	1840-1843	the	_	_	_	_
11-22	1844-1850	latter	_	_	_	_
11-23	1851-1854	for	_	_	_	_
11-24	1855-1858	the	abstract[88]	new[88]	_	_
11-25	1859-1867	presence	abstract[88]	new[88]	_	_
11-26	1868-1870	of	abstract[88]	new[88]	_	_
11-27	1871-1874	two	abstract[88]|person[90]	new[88]|new[90]	coref	25-16[211_90]
11-28	1875-1881	methyl	abstract[88]|organization|person[90]	new[88]|new|new[90]	_	_
11-29	1882-1888	groups	abstract[88]|person[90]	new[88]|new[90]	_	_
11-30	1889-1890	.	_	_	_	_

#Text=Its increased lipophilicity accounts for its ability to reach higher tissue levels in comparison to resveratrol ’s .
12-1	1891-1894	Its	substance|abstract[93]	giv|new[93]	ana|ana	12-6|12-6
12-2	1895-1904	increased	abstract[93]	new[93]	_	_
12-3	1905-1918	lipophilicity	substance|abstract[93]	new|new[93]	_	_
12-4	1919-1927	accounts	abstract[93]	new[93]	_	_
12-5	1928-1931	for	abstract[93]	new[93]	_	_
12-6	1932-1935	its	abstract[93]|substance|abstract[95]	new[93]|giv|new[95]	coref|coref	23-9[196_95]|23-9[196_95]
12-7	1936-1943	ability	abstract[93]|abstract[95]	new[93]|new[95]	_	_
12-8	1944-1946	to	_	_	_	_
12-9	1947-1952	reach	_	_	_	_
12-10	1953-1959	higher	abstract[97]	new[97]	coref	27-25[234_97]
12-11	1960-1966	tissue	object|abstract[97]	new|new[97]	coref	15-41[127_0]
12-12	1967-1973	levels	abstract[97]	new[97]	_	_
12-13	1974-1976	in	_	_	_	_
12-14	1977-1987	comparison	abstract[98]	new[98]	_	_
12-15	1988-1990	to	abstract[98]	new[98]	_	_
12-16	1991-2002	resveratrol	abstract[98]|object[99]	new[98]|giv[99]	_	_
12-17	2003-2005	’s	abstract[98]|object[99]	new[98]|giv[99]	_	_
12-18	2006-2007	.	_	_	_	_

#Text=Moreover , there is no concern about its safety .
13-1	2008-2016	Moreover	_	_	_	_
13-2	2017-2018	,	_	_	_	_
13-3	2019-2024	there	_	_	_	_
13-4	2025-2027	is	_	_	_	_
13-5	2028-2030	no	abstract[100]	new[100]	_	_
13-6	2031-2038	concern	abstract[100]	new[100]	_	_
13-7	2039-2044	about	abstract[100]	new[100]	_	_
13-8	2045-2048	its	abstract[100]|abstract[101]	new[100]|giv[101]	_	_
13-9	2049-2055	safety	abstract[100]|abstract[101]	new[100]|giv[101]	_	_
13-10	2056-2057	.	_	_	_	_

#Text=Pterostilbene has already been shown to have positive effects in combating obesity and related disorders .
14-1	2058-2071	Pterostilbene	substance	giv	coref	15-7
14-2	2072-2075	has	_	_	_	_
14-3	2076-2083	already	_	_	_	_
14-4	2084-2088	been	_	_	_	_
14-5	2089-2094	shown	_	_	_	_
14-6	2095-2097	to	_	_	_	_
14-7	2098-2102	have	_	_	_	_
14-8	2103-2111	positive	abstract[103]	giv[103]	coref	16-5[134_103]
14-9	2112-2119	effects	abstract[103]	giv[103]	_	_
14-10	2120-2122	in	_	_	_	_
14-11	2123-2132	combating	_	_	_	_
14-12	2133-2140	obesity	abstract|abstract[105]	giv|giv[105]	coref|coref|coref|coref	15-5|17-7[140_105]|15-5|17-7[140_105]
14-13	2141-2144	and	abstract[105]	giv[105]	_	_
14-14	2145-2152	related	abstract[105]|abstract[106]	giv[105]|giv[106]	_	_
14-15	2153-2162	disorders	abstract[105]|abstract[106]	giv[105]|giv[106]	_	_
14-16	2163-2164	.	_	_	_	_

#Text=In rat models of obesity , Pt reduces fat accumulation and ameliorates liver steatosis modulating lipolysis , lipogenesis , fatty acid oxidation , improves glycemic control by modulating glycolysis , gluconeogenesis , and glucose uptake , increases thermogenic markers in brown adipose tissue , and induces changes in the gut microbiota towards a healthier composition .
15-1	2165-2167	In	_	_	_	_
15-2	2168-2171	rat	animal|abstract[108]	new|new[108]	_	_
15-3	2172-2178	models	abstract[108]	new[108]	_	_
15-4	2179-2181	of	abstract[108]	new[108]	_	_
15-5	2182-2189	obesity	abstract[108]|abstract	new[108]|giv	coref	17-7
15-6	2190-2191	,	_	_	_	_
15-7	2192-2194	Pt	substance	giv	coref	16-3
15-8	2195-2202	reduces	_	_	_	_
15-9	2203-2206	fat	substance|abstract[112]	giv|new[112]	coref|coref	22-8|22-8
15-10	2207-2219	accumulation	abstract[112]	new[112]	_	_
15-11	2220-2223	and	_	_	_	_
15-12	2224-2235	ameliorates	_	_	_	_
15-13	2236-2241	liver	object|abstract[114]|object[115]	new|new[114]|new[115]	_	_
15-14	2242-2251	steatosis	abstract[114]|object[115]	new[114]|new[115]	_	_
15-15	2252-2262	modulating	object[115]	new[115]	_	_
15-16	2263-2272	lipolysis	object[115]	new[115]	_	_
15-17	2273-2274	,	_	_	_	_
15-18	2275-2286	lipogenesis	substance	new	_	_
15-19	2287-2288	,	_	_	_	_
15-20	2289-2294	fatty	abstract[118]	new[118]	_	_
15-21	2295-2299	acid	substance|abstract[118]	new|new[118]	ana	16-5
15-22	2300-2309	oxidation	abstract[118]	new[118]	_	_
15-23	2310-2311	,	_	_	_	_
15-24	2312-2320	improves	_	_	_	_
15-25	2321-2329	glycemic	abstract|abstract[120]	new|new[120]	_	_
15-26	2330-2337	control	abstract[120]	new[120]	_	_
15-27	2338-2340	by	_	_	_	_
15-28	2341-2351	modulating	_	_	_	_
15-29	2352-2362	glycolysis	substance	new	_	_
15-30	2363-2364	,	_	_	_	_
15-31	2365-2380	gluconeogenesis	substance	new	_	_
15-32	2381-2382	,	_	_	_	_
15-33	2383-2386	and	_	_	_	_
15-34	2387-2394	glucose	substance|abstract[124]	new|new[124]	coref|coref	26-18|26-18
15-35	2395-2401	uptake	abstract[124]	new[124]	_	_
15-36	2402-2403	,	_	_	_	_
15-37	2404-2413	increases	_	_	_	_
15-38	2414-2425	thermogenic	abstract[125]	new[125]	_	_
15-39	2426-2433	markers	abstract[125]	new[125]	_	_
15-40	2434-2436	in	abstract[125]	new[125]	_	_
15-41	2437-2442	brown	abstract[125]|object[127]	new[125]|giv[127]	coref	16-10[0_127]
15-42	2443-2450	adipose	abstract[125]|abstract|object[127]	new[125]|new|giv[127]	coref	16-9
15-43	2451-2457	tissue	abstract[125]|object[127]	new[125]|giv[127]	_	_
15-44	2458-2459	,	_	_	_	_
15-45	2460-2463	and	_	_	_	_
15-46	2464-2471	induces	_	_	_	_
15-47	2472-2479	changes	abstract	giv	_	_
15-48	2480-2482	in	_	_	_	_
15-49	2483-2486	the	place[130]	new[130]	_	_
15-50	2487-2490	gut	abstract|place[130]	new|new[130]	_	_
15-51	2491-2501	microbiota	place[130]	new[130]	_	_
15-52	2502-2509	towards	place[130]	new[130]	_	_
15-53	2510-2511	a	place[130]|abstract[131]	new[130]|new[131]	_	_
15-54	2512-2521	healthier	place[130]|abstract[131]	new[130]|new[131]	_	_
15-55	2522-2533	composition	place[130]|abstract[131]	new[130]|new[131]	_	_
15-56	2534-2535	.	_	_	_	_

#Text=Furthermore , Pt exerts its beneficial effects combating adipose tissue inflammation .
16-1	2536-2547	Furthermore	_	_	_	_
16-2	2548-2549	,	_	_	_	_
16-3	2550-2552	Pt	object	giv	coref	23-12
16-4	2553-2559	exerts	_	_	_	_
16-5	2560-2563	its	substance|abstract[134]	giv|giv[134]	coref|coref	24-1[201_134]|24-1[201_134]
16-6	2564-2574	beneficial	abstract[134]	giv[134]	_	_
16-7	2575-2582	effects	abstract[134]	giv[134]	_	_
16-8	2583-2592	combating	_	_	_	_
16-9	2593-2600	adipose	abstract|abstract[137]	giv|new[137]	coref|coref	18-14|18-14
16-10	2601-2607	tissue	object|abstract[137]	giv|new[137]	_	_
16-11	2608-2620	inflammation	abstract[137]	new[137]	_	_
16-12	2621-2622	.	_	_	_	_

#Text=An interesting therapeutic target for treating obesity and metabolic syndrome is represented by beige ( or brite , i. e. , brown-in-white ) adipocytes .
17-1	2623-2625	An	abstract[138]	new[138]	_	_
17-2	2626-2637	interesting	abstract[138]	new[138]	_	_
17-3	2638-2649	therapeutic	abstract[138]	new[138]	_	_
17-4	2650-2656	target	abstract[138]	new[138]	_	_
17-5	2657-2660	for	_	_	_	_
17-6	2661-2669	treating	_	_	_	_
17-7	2670-2677	obesity	abstract|abstract[140]	giv|giv[140]	coref|coref	21-51|21-51
17-8	2678-2681	and	abstract[140]	giv[140]	_	_
17-9	2682-2691	metabolic	abstract[140]|person|abstract[142]	giv[140]|new|new[142]	_	_
17-10	2692-2700	syndrome	abstract[140]|abstract[142]	giv[140]|new[142]	_	_
17-11	2701-2703	is	_	_	_	_
17-12	2704-2715	represented	_	_	_	_
17-13	2716-2718	by	_	_	_	_
17-14	2719-2724	beige	substance	new	_	_
17-15	2725-2726	(	_	_	_	_
17-16	2727-2729	or	_	_	_	_
17-17	2730-2735	brite	abstract	new	_	_
17-18	2736-2737	,	_	_	_	_
17-19	2738-2740	i.	_	_	_	_
17-20	2741-2743	e.	_	_	_	_
17-21	2744-2745	,	_	_	_	_
17-22	2746-2760	brown-in-white	abstract	new	_	_
17-23	2761-2762	)	_	_	_	_
17-24	2763-2773	adipocytes	object	new	coref	18-8[149_0]
17-25	2774-2775	.	_	_	_	_

#Text=These cells are an inducible form of thermogenic adipocytes residing in subcutaneous white adipose tissue ( WAT ) and are also found in human adults .
18-1	2776-2781	These	object[147]	new[147]	coref	18-4[148_147]
18-2	2782-2787	cells	object[147]	new[147]	_	_
18-3	2788-2791	are	_	_	_	_
18-4	2792-2794	an	object[148]	giv[148]	coref	19-15[159_148]
18-5	2795-2804	inducible	object[148]	giv[148]	_	_
18-6	2805-2809	form	object[148]	giv[148]	_	_
18-7	2810-2812	of	object[148]	giv[148]	_	_
18-8	2813-2824	thermogenic	object[148]|object[149]	giv[148]|giv[149]	coref	19-1[154_149]
18-9	2825-2835	adipocytes	object[148]|object[149]	giv[148]|giv[149]	_	_
18-10	2836-2844	residing	_	_	_	_
18-11	2845-2847	in	_	_	_	_
18-12	2848-2860	subcutaneous	object[151]	new[151]	appos	18-17[0_151]
18-13	2861-2866	white	object[151]	new[151]	_	_
18-14	2867-2874	adipose	abstract|object[151]	giv|new[151]	_	_
18-15	2875-2881	tissue	object[151]	new[151]	_	_
18-16	2882-2883	(	_	_	_	_
18-17	2884-2887	WAT	object	giv	coref	21-9
18-18	2888-2889	)	_	_	_	_
18-19	2890-2893	and	_	_	_	_
18-20	2894-2897	are	_	_	_	_
18-21	2898-2902	also	_	_	_	_
18-22	2903-2908	found	_	_	_	_
18-23	2909-2911	in	_	_	_	_
18-24	2912-2917	human	person[153]	new[153]	ana	20-1[0_153]
18-25	2918-2924	adults	person[153]	new[153]	_	_
18-26	2925-2926	.	_	_	_	_

#Text=Beige adipocytes can derive from white adipocyte trans differentiation and from the differentiation of adipogenic progenitor cells .
19-1	2927-2932	Beige	object[154]	giv[154]	coref	20-20[165_154]
19-2	2933-2943	adipocytes	object[154]	giv[154]	_	_
19-3	2944-2947	can	_	_	_	_
19-4	2948-2954	derive	_	_	_	_
19-5	2955-2959	from	_	_	_	_
19-6	2960-2965	white	abstract[157]	new[157]	coref	19-12[158_157]
19-7	2966-2975	adipocyte	object|abstract[157]	new|new[157]	_	_
19-8	2976-2981	trans	person|abstract[157]	new|new[157]	_	_
19-9	2982-2997	differentiation	abstract[157]	new[157]	_	_
19-10	2998-3001	and	_	_	_	_
19-11	3002-3006	from	_	_	_	_
19-12	3007-3010	the	abstract[158]	giv[158]	_	_
19-13	3011-3026	differentiation	abstract[158]	giv[158]	_	_
19-14	3027-3029	of	abstract[158]	giv[158]	_	_
19-15	3030-3040	adipogenic	abstract[158]|object[159]	giv[158]|giv[159]	_	_
19-16	3041-3051	progenitor	abstract[158]|object[159]	giv[158]|giv[159]	_	_
19-17	3052-3057	cells	abstract[158]|object[159]	giv[158]|giv[159]	_	_
19-18	3058-3059	.	_	_	_	_

#Text=They express a set of beige-specific genes , such as Cited1 and Tbx1 , but also have similarities with brown adipocytes , including abundant mitochondria , multilocular lipid droplets and expression of brown-specific genes such as uncoupling protein 1 ( UCP1 ) and Cidea ; similar to brown adipocytes , they are able to dissipate energy as heat .
20-1	3060-3064	They	person	giv	ana	20-51
20-2	3065-3072	express	_	_	_	_
20-3	3073-3074	a	abstract[161]	new[161]	coref	20-33[170_161]
20-4	3075-3078	set	abstract[161]	new[161]	_	_
20-5	3079-3081	of	abstract[161]	new[161]	_	_
20-6	3082-3096	beige-specific	abstract[161]	new[161]	_	_
20-7	3097-3102	genes	abstract[161]	new[161]	_	_
20-8	3103-3104	,	abstract[161]	new[161]	_	_
20-9	3105-3109	such	abstract[161]	new[161]	_	_
20-10	3110-3112	as	abstract[161]	new[161]	_	_
20-11	3113-3119	Cited1	abstract[161]|abstract	new[161]|new	_	_
20-12	3120-3123	and	abstract[161]	new[161]	_	_
20-13	3124-3128	Tbx1	abstract[161]|abstract	new[161]|new	_	_
20-14	3129-3130	,	_	_	_	_
20-15	3131-3134	but	_	_	_	_
20-16	3135-3139	also	_	_	_	_
20-17	3140-3144	have	_	_	_	_
20-18	3145-3157	similarities	abstract[164]	new[164]	_	_
20-19	3158-3162	with	abstract[164]	new[164]	_	_
20-20	3163-3168	brown	abstract[164]|object[165]	new[164]|giv[165]	coref	20-48[174_165]
20-21	3169-3179	adipocytes	abstract[164]|object[165]	new[164]|giv[165]	_	_
20-22	3180-3181	,	abstract[164]|object[165]	new[164]|giv[165]	_	_
20-23	3182-3191	including	abstract[164]|object[165]	new[164]|giv[165]	_	_
20-24	3192-3200	abundant	abstract[164]|object[165]|object[166]	new[164]|giv[165]|new[166]	_	_
20-25	3201-3213	mitochondria	abstract[164]|object[165]|object[166]	new[164]|giv[165]|new[166]	_	_
20-26	3214-3215	,	abstract[164]|object[165]	new[164]|giv[165]	_	_
20-27	3216-3228	multilocular	abstract[164]|object[165]|object[168]	new[164]|giv[165]|new[168]	_	_
20-28	3229-3234	lipid	abstract[164]|object[165]|person|object[168]	new[164]|giv[165]|new|new[168]	_	_
20-29	3235-3243	droplets	abstract[164]|object[165]|object[168]	new[164]|giv[165]|new[168]	_	_
20-30	3244-3247	and	abstract[164]|object[165]	new[164]|giv[165]	_	_
20-31	3248-3258	expression	abstract[164]|object[165]|abstract[169]	new[164]|giv[165]|new[169]	_	_
20-32	3259-3261	of	abstract[164]|object[165]|abstract[169]	new[164]|giv[165]|new[169]	_	_
20-33	3262-3276	brown-specific	abstract[164]|object[165]|abstract[169]|abstract[170]	new[164]|giv[165]|new[169]|giv[170]	coref	27-21[231_170]
20-34	3277-3282	genes	abstract[164]|object[165]|abstract[169]|abstract[170]	new[164]|giv[165]|new[169]|giv[170]	_	_
20-35	3283-3287	such	abstract[164]|object[165]|abstract[169]|abstract[170]	new[164]|giv[165]|new[169]|giv[170]	_	_
20-36	3288-3290	as	abstract[164]|object[165]|abstract[169]|abstract[170]	new[164]|giv[165]|new[169]|giv[170]	_	_
20-37	3291-3301	uncoupling	abstract[164]|object[165]|abstract[169]|abstract[170]|substance[171]	new[164]|giv[165]|new[169]|giv[170]|new[171]	coref	27-26[0_171]
20-38	3302-3309	protein	abstract[164]|object[165]|abstract[169]|abstract[170]|substance[171]	new[164]|giv[165]|new[169]|giv[170]|new[171]	_	_
20-39	3310-3311	1	abstract[164]|object[165]|abstract[169]|abstract[170]|substance[171]	new[164]|giv[165]|new[169]|giv[170]|new[171]	_	_
20-40	3312-3313	(	_	_	_	_
20-41	3314-3318	UCP1	organization	new	coref	27-25
20-42	3319-3320	)	_	_	_	_
20-43	3321-3324	and	_	_	_	_
20-44	3325-3330	Cidea	substance[173]	new[173]	_	_
20-45	3331-3332	;	substance[173]	new[173]	_	_
20-46	3333-3340	similar	substance[173]	new[173]	_	_
20-47	3341-3343	to	_	_	_	_
20-48	3344-3349	brown	object[174]	giv[174]	coref	21-3[178_174]
20-49	3350-3360	adipocytes	object[174]	giv[174]	_	_
20-50	3361-3362	,	_	_	_	_
20-51	3363-3367	they	person	giv	_	_
20-52	3368-3371	are	_	_	_	_
20-53	3372-3376	able	_	_	_	_
20-54	3377-3379	to	_	_	_	_
20-55	3380-3389	dissipate	_	_	_	_
20-56	3390-3396	energy	abstract	new	_	_
20-57	3397-3399	as	_	_	_	_
20-58	3400-3404	heat	_	_	_	_
20-59	3405-3406	.	_	_	_	_

#Text=Induction of beige adipocytes ( i. e. , WAT browning ) can be induced by environmental or physiological stimuli ( such as cold exposure , physical activity , or thyroid hormones ) , but also pharmacologically ( for example , with PPAR agonists ) , and could prevent or combat obesity by increasing energy consumption through non-shivering thermogenesis .
21-1	3407-3416	Induction	abstract[177]	new[177]	_	_
21-2	3417-3419	of	abstract[177]	new[177]	_	_
21-3	3420-3425	beige	abstract[177]|object[178]	new[177]|giv[178]	coref	24-7[202_178]
21-4	3426-3436	adipocytes	abstract[177]|object[178]	new[177]|giv[178]	_	_
21-5	3437-3438	(	_	_	_	_
21-6	3439-3441	i.	_	_	_	_
21-7	3442-3444	e.	_	_	_	_
21-8	3445-3446	,	_	_	_	_
21-9	3447-3450	WAT	abstract|abstract[180]	giv|new[180]	coref|coref|coref|coref	22-8[193_180]|23-17|22-8[193_180]|23-17
21-10	3451-3459	browning	abstract[180]	new[180]	_	_
21-11	3460-3461	)	_	_	_	_
21-12	3462-3465	can	_	_	_	_
21-13	3466-3468	be	_	_	_	_
21-14	3469-3476	induced	_	_	_	_
21-15	3477-3479	by	_	_	_	_
21-16	3480-3493	environmental	abstract[181]	new[181]	_	_
21-17	3494-3496	or	abstract[181]	new[181]	_	_
21-18	3497-3510	physiological	abstract[181]	new[181]	_	_
21-19	3511-3518	stimuli	abstract[181]	new[181]	_	_
21-20	3519-3520	(	abstract[181]	new[181]	_	_
21-21	3521-3525	such	abstract[181]	new[181]	_	_
21-22	3526-3528	as	abstract[181]	new[181]	_	_
21-23	3529-3533	cold	abstract[181]|abstract[182]	new[181]|new[182]	_	_
21-24	3534-3542	exposure	abstract[181]|abstract[182]	new[181]|new[182]	_	_
21-25	3543-3544	,	abstract[181]	new[181]	_	_
21-26	3545-3553	physical	abstract[181]|abstract[183]	new[181]|giv[183]	_	_
21-27	3554-3562	activity	abstract[181]|abstract[183]	new[181]|giv[183]	_	_
21-28	3563-3564	,	abstract[181]	new[181]	_	_
21-29	3565-3567	or	abstract[181]	new[181]	_	_
21-30	3568-3575	thyroid	abstract[181]|object|substance[185]	new[181]|new|new[185]	_	_
21-31	3576-3584	hormones	abstract[181]|substance[185]	new[181]|new[185]	_	_
21-32	3585-3586	)	abstract[181]	new[181]	_	_
21-33	3587-3588	,	_	_	_	_
21-34	3589-3592	but	_	_	_	_
21-35	3593-3597	also	_	_	_	_
21-36	3598-3615	pharmacologically	_	_	_	_
21-37	3616-3617	(	_	_	_	_
21-38	3618-3621	for	_	_	_	_
21-39	3622-3629	example	_	_	_	_
21-40	3630-3631	,	_	_	_	_
21-41	3632-3636	with	_	_	_	_
21-42	3637-3641	PPAR	organization|substance[187]	new|new[187]	_	_
21-43	3642-3650	agonists	substance[187]	new[187]	_	_
21-44	3651-3652	)	_	_	_	_
21-45	3653-3654	,	_	_	_	_
21-46	3655-3658	and	_	_	_	_
21-47	3659-3664	could	_	_	_	_
21-48	3665-3672	prevent	_	_	_	_
21-49	3673-3675	or	_	_	_	_
21-50	3676-3682	combat	_	_	_	_
21-51	3683-3690	obesity	abstract	giv	coref	24-18[205_0]
21-52	3691-3693	by	_	_	_	_
21-53	3694-3704	increasing	_	_	_	_
21-54	3705-3711	energy	abstract[189]	new[189]	_	_
21-55	3712-3723	consumption	abstract[189]	new[189]	_	_
21-56	3724-3731	through	_	_	_	_
21-57	3732-3745	non-shivering	abstract[190]	new[190]	_	_
21-58	3746-3759	thermogenesis	abstract[190]	new[190]	_	_
21-59	3760-3761	.	_	_	_	_

#Text=Various phytochemicals have been reported to promote fat browning .
22-1	3762-3769	Various	abstract[191]	new[191]	_	_
22-2	3770-3784	phytochemicals	abstract[191]	new[191]	_	_
22-3	3785-3789	have	_	_	_	_
22-4	3790-3794	been	_	_	_	_
22-5	3795-3803	reported	_	_	_	_
22-6	3804-3806	to	_	_	_	_
22-7	3807-3814	promote	_	_	_	_
22-8	3815-3818	fat	substance|abstract[193]	giv|giv[193]	_	_
22-9	3819-3827	browning	abstract[193]	giv[193]	_	_
22-10	3828-3829	.	_	_	_	_

#Text=The aim of this study was to investigate the ability of Pt to do it in WAT .
23-1	3830-3833	The	abstract[194]	new[194]	_	_
23-2	3834-3837	aim	abstract[194]	new[194]	_	_
23-3	3838-3840	of	abstract[194]	new[194]	_	_
23-4	3841-3845	this	abstract[194]|abstract[195]	new[194]|new[195]	_	_
23-5	3846-3851	study	abstract[194]|abstract[195]	new[194]|new[195]	_	_
23-6	3852-3855	was	_	_	_	_
23-7	3856-3858	to	_	_	_	_
23-8	3859-3870	investigate	_	_	_	_
23-9	3871-3874	the	abstract[196]	giv[196]	ana	23-15[0_196]
23-10	3875-3882	ability	abstract[196]	giv[196]	_	_
23-11	3883-3885	of	abstract[196]	giv[196]	_	_
23-12	3886-3888	Pt	abstract[196]|object	giv[196]|giv	coref	25-34
23-13	3889-3891	to	_	_	_	_
23-14	3892-3894	do	_	_	_	_
23-15	3895-3897	it	abstract	giv	_	_
23-16	3898-3900	in	_	_	_	_
23-17	3901-3904	WAT	abstract	giv	ana	24-1
23-18	3905-3906	.	_	_	_	_

#Text=Its effects were first assayed on cultured 3T3-L1 adipocytes , and then in a mouse model of diet-induced obesity .
24-1	3907-3910	Its	abstract|abstract[201]	giv|giv[201]	coref|coref	27-8|27-8
24-2	3911-3918	effects	abstract[201]	giv[201]	_	_
24-3	3919-3923	were	_	_	_	_
24-4	3924-3929	first	_	_	_	_
24-5	3930-3937	assayed	_	_	_	_
24-6	3938-3940	on	_	_	_	_
24-7	3941-3949	cultured	object[202]	giv[202]	_	_
24-8	3950-3956	3T3-L1	object[202]	giv[202]	_	_
24-9	3957-3967	adipocytes	object[202]	giv[202]	_	_
24-10	3968-3969	,	_	_	_	_
24-11	3970-3973	and	_	_	_	_
24-12	3974-3978	then	_	_	_	_
24-13	3979-3981	in	_	_	_	_
24-14	3982-3983	a	abstract[204]	new[204]	_	_
24-15	3984-3989	mouse	animal|abstract[204]	new|new[204]	_	_
24-16	3990-3995	model	abstract[204]	new[204]	_	_
24-17	3996-3998	of	abstract[204]	new[204]	_	_
24-18	3999-4011	diet-induced	abstract[204]|abstract[205]	new[204]|giv[205]	_	_
24-19	4012-4019	obesity	abstract[204]|abstract[205]	new[204]|giv[205]	_	_
24-20	4020-4021	.	_	_	_	_

#Text=To take into account possible gender-specific differences , both females and males were included in our experimental groups ; a 30 week-long treatment was performed , to highlight long-term effects of a chronic Pt supplementation .
25-1	4022-4024	To	_	_	_	_
25-2	4025-4029	take	_	_	_	_
25-3	4030-4034	into	_	_	_	_
25-4	4035-4042	account	abstract	new	_	_
25-5	4043-4051	possible	abstract[207]	new[207]	_	_
25-6	4052-4067	gender-specific	abstract[207]	new[207]	_	_
25-7	4068-4079	differences	abstract[207]	new[207]	_	_
25-8	4080-4081	,	_	_	_	_
25-9	4082-4086	both	person[208]	new[208]	_	_
25-10	4087-4094	females	person[208]	new[208]	_	_
25-11	4095-4098	and	_	_	_	_
25-12	4099-4104	males	person	new	_	_
25-13	4105-4109	were	_	_	_	_
25-14	4110-4118	included	_	_	_	_
25-15	4119-4121	in	_	_	_	_
25-16	4122-4125	our	person|person[211]	giv|giv[211]	ana|ana	26-1|26-1
25-17	4126-4138	experimental	person[211]	giv[211]	_	_
25-18	4139-4145	groups	person[211]	giv[211]	_	_
25-19	4146-4147	;	_	_	_	_
25-20	4148-4149	a	event[212]	giv[212]	_	_
25-21	4150-4152	30	event[212]	giv[212]	_	_
25-22	4153-4162	week-long	event[212]	giv[212]	_	_
25-23	4163-4172	treatment	event[212]	giv[212]	_	_
25-24	4173-4176	was	_	_	_	_
25-25	4177-4186	performed	_	_	_	_
25-26	4187-4188	,	_	_	_	_
25-27	4189-4191	to	_	_	_	_
25-28	4192-4201	highlight	_	_	_	_
25-29	4202-4211	long-term	abstract[213]	new[213]	_	_
25-30	4212-4219	effects	abstract[213]	new[213]	_	_
25-31	4220-4222	of	abstract[213]	new[213]	_	_
25-32	4223-4224	a	abstract[213]|abstract[215]	new[213]|new[215]	_	_
25-33	4225-4232	chronic	abstract[213]|abstract[215]	new[213]|new[215]	_	_
25-34	4233-4235	Pt	abstract[213]|substance|abstract[215]	new[213]|giv|new[215]	coref	26-4
25-35	4236-4251	supplementation	abstract[213]|abstract[215]	new[213]|new[215]	_	_
25-36	4252-4253	.	_	_	_	_

#Text=We found that Pt diminished body weight gain induced by a high-fat diet regimen ; also , glucose homeostasis was partially preserved , at least up to week 18 .
26-1	4254-4256	We	person	giv	_	_
26-2	4257-4262	found	_	_	_	_
26-3	4263-4267	that	_	_	_	_
26-4	4268-4270	Pt	substance|abstract[220]	giv|new[220]	coref|coref	27-3|27-3
26-5	4271-4281	diminished	abstract[220]	new[220]	_	_
26-6	4282-4286	body	object|abstract[220]	new|new[220]	_	_
26-7	4287-4293	weight	abstract|abstract[220]	new|new[220]	_	_
26-8	4294-4298	gain	abstract[220]	new[220]	_	_
26-9	4299-4306	induced	_	_	_	_
26-10	4307-4309	by	_	_	_	_
26-11	4310-4311	a	event[222]	new[222]	_	_
26-12	4312-4320	high-fat	event[222]	new[222]	_	_
26-13	4321-4325	diet	event|event[222]	new|new[222]	_	_
26-14	4326-4333	regimen	event[222]	new[222]	_	_
26-15	4334-4335	;	_	_	_	_
26-16	4336-4340	also	_	_	_	_
26-17	4341-4342	,	_	_	_	_
26-18	4343-4350	glucose	substance|abstract[224]	giv|new[224]	_	_
26-19	4351-4362	homeostasis	abstract[224]	new[224]	_	_
26-20	4363-4366	was	_	_	_	_
26-21	4367-4376	partially	_	_	_	_
26-22	4377-4386	preserved	_	_	_	_
26-23	4387-4388	,	_	_	_	_
26-24	4389-4391	at	_	_	_	_
26-25	4392-4397	least	_	_	_	_
26-26	4398-4400	up	_	_	_	_
26-27	4401-4403	to	_	_	_	_
26-28	4404-4408	week	time[225]	new[225]	_	_
26-29	4409-4411	18	time[225]	new[225]	_	_
26-30	4412-4413	.	_	_	_	_

#Text=Interestingly , Pt was able to induce WAT browning , leading to an increase in the transcription of beige- and brown-related genes and of UCP1 protein levels , which , however , did not achieve significance .
27-1	4414-4427	Interestingly	_	_	_	_
27-2	4428-4429	,	_	_	_	_
27-3	4430-4432	Pt	abstract	giv	_	_
27-4	4433-4436	was	_	_	_	_
27-5	4437-4441	able	_	_	_	_
27-6	4442-4444	to	_	_	_	_
27-7	4445-4451	induce	_	_	_	_
27-8	4452-4455	WAT	abstract	giv	_	_
27-9	4456-4464	browning	_	_	_	_
27-10	4465-4466	,	_	_	_	_
27-11	4467-4474	leading	_	_	_	_
27-12	4475-4477	to	_	_	_	_
27-13	4478-4480	an	abstract[228]	new[228]	_	_
27-14	4481-4489	increase	abstract[228]	new[228]	_	_
27-15	4490-4492	in	abstract[228]	new[228]	_	_
27-16	4493-4496	the	abstract[228]|abstract[229]	new[228]|new[229]	_	_
27-17	4497-4510	transcription	abstract[228]|abstract[229]	new[228]|new[229]	_	_
27-18	4511-4513	of	abstract[228]|abstract[229]	new[228]|new[229]	_	_
27-19	4514-4520	beige-	abstract[228]|abstract[229]|abstract	new[228]|new[229]|new	_	_
27-20	4521-4524	and	abstract[228]|abstract[229]	new[228]|new[229]	_	_
27-21	4525-4538	brown-related	abstract[228]|abstract[229]|abstract[231]	new[228]|new[229]|giv[231]	_	_
27-22	4539-4544	genes	abstract[228]|abstract[229]|abstract[231]	new[228]|new[229]|giv[231]	_	_
27-23	4545-4548	and	abstract[228]|abstract[229]	new[228]|new[229]	_	_
27-24	4549-4551	of	abstract[228]|abstract[229]	new[228]|new[229]	_	_
27-25	4552-4556	UCP1	abstract[228]|abstract[229]|abstract|abstract[234]	new[228]|new[229]|giv|giv[234]	_	_
27-26	4557-4564	protein	abstract[228]|abstract[229]|substance|abstract[234]	new[228]|new[229]|giv|giv[234]	_	_
27-27	4565-4571	levels	abstract[228]|abstract[229]|abstract[234]	new[228]|new[229]|giv[234]	_	_
27-28	4572-4573	,	_	_	_	_
27-29	4574-4579	which	_	_	_	_
27-30	4580-4581	,	_	_	_	_
27-31	4582-4589	however	_	_	_	_
27-32	4590-4591	,	_	_	_	_
27-33	4592-4595	did	_	_	_	_
27-34	4596-4599	not	_	_	_	_
27-35	4600-4607	achieve	_	_	_	_
27-36	4608-4620	significance	abstract	new	_	_
27-37	4621-4622	.	_	_	_	_
